Juventas Therapeutics Enrolls First Patient in Phase 2 Gene Therapy Clinical Trial for Treatment of Advanced Peripheral Artery ...
CLEVELAND, OH -- (Marketwired) -- 02/04/16 -- Juventas Therapeutics, Inc., a clinical-stage gene therapy company, announced that it is enrolling its STOP-PAD trial, a 120-patient, placebo-controlled, randomized double-blinded Phase 2 study evaluating the …